AVITA Medical has successfully raised approximately A$23 million through a private placement, positioning the company to advance its therapeutic acute wound care portfolio and target free cash flow by 2026.
AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.
